α-1 antitrypsin deficiency: current and future treatment options

Bibliography

• Laurell CB, Eriksson S. “The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency”. Scand J Clin Lab Invest 1963;15(2):132-40
   Web of Science ®Google Scholar
• Sveger T. Liver Disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-21
   PubMed Web of Science ®Google Scholar
• Edmonds BK, Hodge JA, Rietschel RL. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol 1991;8(4):296-9
   Google Scholar
• Morris H, Morgan MD, Wood AM, et al. ANCA-associated vasculitis is linked to carriage of the Z allele of alpha1 antitrypsin and its polymers. Ann Rheum Dis 2011;70(10):1851-6
   PubMed Web of Science ®Google Scholar
• Schievink WI, Katzmann JA, Piepgras DG, Schaid DJ. Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. J Neurosurg 1996;84(5):781-4
   Google Scholar
• Schievink WI, Puumala MR, Meyer FB, et al. Giant intracranial aneurysm and fibromuscular dysplasia in an adolescent with alpha 1-antitrypsin deficiency. J Neurosurg 1996;85(3):503-6
   Google Scholar
• King MA, Stone JA, Diaz PT, et al. Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 1996;199(1):137-41
   Google Scholar
• Yang P, Bamlet WR, Sun Z, et al. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005;128(1):445-52
   Google Scholar
• Davis ID, Burke B, Freese D, et al. The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency. Hum Pathol 1992;23(1):57-62
   Google Scholar
• Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD 2013;10(Suppl 1):60-3; Review
   PubMedGoogle Scholar
• Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749-57; Review
   PubMed Web of Science ®Google Scholar
• Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2012;185(3):246-59; Review
   PubMed Web of Science ®Google Scholar
• Wewers MD, Crystal RG. Alpha-1 antitrypsin augmentation therapy. COPD 2013;10(Suppl 1):64-7; Review
   PubMedGoogle Scholar
• Brantly ML, Paul LD, Miller BH, et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138:327-36
   PubMed Web of Science ®Google Scholar
• Carrell RW. Alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest 1986;78:1427-31
   PubMed Web of Science ®Google Scholar
• Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980;255:3931-4
   PubMed Web of Science ®Google Scholar
• Rao NV, Wehner NG, Marshall BC, et al. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 1991;266:9540-8
   PubMed Web of Science ®Google Scholar
• Bergin DA, Reeves EP, Meleady P, et al. Alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120(12):4236-50
   PubMed Web of Science ®Google Scholar
• DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59(3):259-64. Review
   PubMed Web of Science ®Google Scholar
• Curiel DT, Holmes MD, Okayama H, et al. Molecular basis of the liver and lung disease associated with the alpha 1-antitrypsin deficiency allele Mmalton. J Biol Chem 1989;264(23):13938-45
   Google Scholar
• Curiel DT, Chytil A, Courtney M, Crystal RG. Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264 – Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J Biol Chem 1989;264(18):10477-86
   Google Scholar
• Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992;357(6379):605-7
   PubMed Web of Science ®Google Scholar
• Fregonese L, Stolk J, Frants RR, Veldhuisen B. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 2008;102(6):876-84
   PubMed Web of Science ®Google Scholar
• Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008;3:16; Review
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990;85(5):1343-52; Review
   Google Scholar
• Hubbard RC, Crystal RG. Augmentation therapy of alpha 1-antitrypsin deficiency. Eur Respir J Suppl 1990;9:44s-52s
   PubMedGoogle Scholar
• Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189(4):419-27
   PubMed Web of Science ®Google Scholar
• Cacciottolo TM, Gelson WT, Maguire G, et al. Pi*Z heterozygous alpha-1 antitrypsin states accelerate parenchymal but not biliary cirrhosis. Eur J Gastroenterol Hepatol 2014;26(4):412-17
   Google Scholar
• Carroll TP, Greene CM, O’Connor CA, et al. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol 2010;184(8):4538-46
   PubMed Web of Science ®Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316(17):1055-62
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988;260(9):1259-64
   PubMed Web of Science ®Google Scholar
• Seersholm N, Wencker M, Banik N, et al. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Eur Respir J 1997;10(10):2260-3
   PubMed Web of Science ®Google Scholar
• The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998;158(1):49-59
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-72
   PubMed Web of Science ®Google Scholar
• Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009;33(6):1345-53
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JGW, Piitulainen E, RAPID Trial Study Group. IV alpha1 antitrypsin (a1at) preserves lung density in homozygous alpha1 antitrypsin deficiency (a1atd); a randomized, placebo-controlled trial. C20 late breaking abstracts in clinical trials, American Thoracic Society 2013, Philadelphia, PA., USA; Mini Symposium 21 May 2013
   Google Scholar
• Hubbard RC, Brantly ML, Sellers SE, et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989;111(3):206-12
   PubMed Web of Science ®Google Scholar
• Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989;84(4):1349-54
   PubMed Web of Science ®Google Scholar
• Casolaro MA, Fells G, Wewers M, et al. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol (1985) 1987;63(5):2015-23
   PubMed Web of Science ®Google Scholar
• Döring G. Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis. Pediatr Pulmonol 1999;28(5):363-75; Review
   Google Scholar
• Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest 1989;84(4):1145-54
   PubMed Web of Science ®Google Scholar
• Spencer LT, Humphries JE, Brantly ML; Transgenic Human Alpha 1-Antitrypsin Study Group. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med 2005;352(19):2030-1
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Stocks J, Rouhani FN, et al. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous). COPD 2014;11(1):17-25
   PubMedGoogle Scholar
• McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90(4):1296-301
   PubMed Web of Science ®Google Scholar
• Birrer P, McElvaney NG, Rüdeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150(1):207-13
   PubMed Web of Science ®Google Scholar
• Garver RIJr, Chytil A, Courtney M, Crystal RG. Clonal gene therapy: transplanted mouse fibroblast clones express human alpha 1-antitrypsin gene in vivo. Science 1987;237(4816):762-4
   Google Scholar
• Garver RIJr, Chytil A, Karlsson S, et al. Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector. Proc Natl Acad Sci USA 1987;84(4):1050-4
   Google Scholar
• Jones EA, Vergalla J, Steer CJ, et al. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med 1978;55(2):139-48
   PubMedGoogle Scholar
• Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000;11(7):1023-32
   PubMed Web of Science ®Google Scholar
• Eggenschwiler R, Loya K, Wu G, et al. Sustained knockdown of a disease-causing gene in patient-specific induced pluripotent stem cells using lentiviral vector-based gene therapy. Stem Cells Transl Med 2013;2(9):641-54
   Google Scholar
• Wilson AA, Murphy GJ, Hamakawa H, et al. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest 2010;120(1):379-89
   PubMed Web of Science ®Google Scholar
• Somers A, Jean JC, Sommer CA, et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28(10):1728-40
   PubMed Web of Science ®Google Scholar
• Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991;252(5004):431-4
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Crystal RG. IL-6 release and airway administration of human CFR cDNA adenovirus vector. Nat Med 1995;1(3):182-4
   PubMed Web of Science ®Google Scholar
• Podsakoff G, Wong KKJr, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994;68(9):5656-66
   PubMed Web of Science ®Google Scholar
• Song S, Embury J, Laipis PJ, et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2001;8(17):1299-306
   PubMed Web of Science ®Google Scholar
• Song S. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998;95:14384-8
   PubMed Web of Science ®Google Scholar
• Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011;22(10):1239-47
   PubMed Web of Science ®Google Scholar
• Chiuchiolo MJ, Kaminsky SM, Sondhi D, et al. Intrapleural administration of an AAVrh.10 vector coding for human alpha1-antitrypsin for the treatment of alpha1-antitrypsin deficiency. Hum Gene Ther Clin Dev 2013;24(4):161-73
   PubMed Web of Science ®Google Scholar
• De BP, Heguy A, Hackett NR, et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006;13(1):67-76
   PubMed Web of Science ®Google Scholar
• Zern MA, Ozaki I, Duan L, et al. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther 1999;6(1):114-20
   Google Scholar
• Duan YY, Wu J, Zhu JL, et al. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology 2004;127(4):1222-32; Erratum in: Gastroenterology. 2005 Mar;128(3):808
   Google Scholar
• Mueller C, Tang Q, Gruntman A, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 2012;20(3):590-600
   PubMed Web of Science ®Google Scholar
• The International Society for Heart and Lung Transplantation. “Adult Lung TransplantationStatistics”. Available from: http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry&year=2014
   Google Scholar
• Low DE, Trulock EP, Kaiser LR, et al. Morbidity, mortality, and early results of single versus bilateral lung transplantation for emphysema. J Thorac Cardiovasc Surg 1992;103(6):1119-26
   Google Scholar
• Mal H, Andreassian B, Pamela F, et al. Unilateral lung transplantation in end-stage pulmonary emphysema. Am Rev Respir Dis 1989;140(3):797-802
   PubMed Web of Science ®Google Scholar
• Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis 1989;139(2):303-7
   PubMed Web of Science ®Google Scholar
• Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function after lung transplantation for alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2014;190(3):274-81
   PubMed Web of Science ®Google Scholar
• King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994;149(4 Pt 1):966-71
   PubMed Web of Science ®Google Scholar
• Lomas DA, Finch JT, Seyama K, et al. Alpha1-Antitrypsin Siiyama (Ser53→Phe): further evidence for intracellular loop-sheet polymerization. J Biol Chem 1993;268:15333-5
   PubMed Web of Science ®Google Scholar
• Lomas DA, Elliott PR, Sidhar SK, et al. Alpha1-antitrypsin Mmalton (Phe52 deleted) forms loop sheet polymers in vivo: evidence for the C sheet mechanism of polymerization. J Biol Chem 1995;270:16864-70
   PubMed Web of Science ®Google Scholar
• Elliott PR, Stein PE, Bilton D, et al. Structural explanation for the dysfunction of S alpha1-antitrypsin. Nat Struct Biol 1996;3:910-11
   PubMedGoogle Scholar
• Elliott PR, Lomas DA, Carrell RW, Abrahams J-P. Inhibitory conformation of the reactive loop of alpha1-antitrypsin. Nat Struct Biol 1996;3:676-81
   PubMedGoogle Scholar
• Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 2007;50(22):5357-63
   PubMed Web of Science ®Google Scholar
• Bouchecareilh M, Hutt DM, Szajner P, et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha1-antitrypsin deficiency. J Biol Chem 2012;287(45):38265-78
   PubMedGoogle Scholar
• Devlin GL, Parfrey H, Tew DJ, et al. Prevention of polymerization of M and Z alpha1-antitrypsin (alpha1-AT) with Trimethylamine N-Oxide. Implications for the treatment of alpha1-AT deficiency. Am J Respir Cell Mol Biol 2001;24:727-32
   PubMed Web of Science ®Google Scholar
• Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha1-antitrypsin (alpha1-AT) Z: a potential pharmacologcial strategy for prevention of liver injury and emphysema. Proc Natl Acad Sci USA 2000;97:1796-801
   PubMed Web of Science ®Google Scholar
• Chang YP, Mahadeva R, Chang WS, et al. Identification of a 4-mer peptide inhibitor that effectively blocks the polymerization of pathogenic Z alpha1-antitrypsin. Am J Respir Cell Mol Biol 2006;35:540-8
   PubMed Web of Science ®Google Scholar
• Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr 2004;39(1):34-7
   PubMed Web of Science ®Google Scholar
• Ding J, Yannam GR, Roy-Chowdhury N, et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human alpha1-antitrypsin by wild-type donor hepatocytes. J Clin Invest 2011;121(5):1930-4
   PubMed Web of Science ®Google Scholar
• Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010;329(5988):229-32
   PubMed Web of Science ®Google Scholar
• Hannan NR, Segeritz CP, Touboul T, Vallier L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 2013;8(2):430-7
   PubMed Web of Science ®Google Scholar
• Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478(7369):391-4
   PubMed Web of Science ®Google Scholar
• Sclar DA, Evans MA, Robison LM, Skaer TL. Alpha1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to alpha1-antitrypsin deficiency: number and costs of years of life gained. Clin Drug Investig 2012;32(5):353-60
   PubMed Web of Science ®Google Scholar
• Mullins CD, Huang X, Merchant S, Stoller JK; Alpha One Foundation Research Network. The direct medical costs of alpha(1)-antitrypsin deficiency. Chest 2001;119(3):745-52
   PubMed Web of Science ®Google Scholar
• Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;167(10):1387-92
   PubMed Web of Science ®Google Scholar